tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate | 1228581-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate
• CAS: 1228581-11-0
• 化学式: C₁₀H₁₅FN₂O₂
• 分子量: 214.24
• InChiKey: MPFWJMKSMHVFDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate 在 盐酸 、 溶剂黄146 、 sodium carbonate 作用下， 以 水 、 丙酮 为溶剂， 反应 21.0h， 生成 1-(tert-butoxycarbonyl)-3-(fluoromethyl)azetidine 3-carboxylic acid
  参考文献：
  名称：

  2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR

  摘要：

  公开号：

  EP2354134B1
• 作为产物：
  描述：

  1-Boc-3-氰基氮杂环丁烷 在 正丁基锂 、 二乙胺基三氟化硫 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate
  参考文献：
  名称：

  2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR

  摘要：

  公开号：

  EP2354134B1

文献信息

• [EN] DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK<br/>[FR] COMPOSÉS DE DIHYDROPYRROLONAPHTYRIDINONE COMME INHIBITEURS DE JAK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010144486A1

  公开（公告）日：2010-12-16

  Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  揭示了式(I)的JAK抑制剂，其中G1、R1、R2、R3、R4、R5、R6和R7在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗涉及免疫系统和炎症的疾病、紊乱和症状的方法，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他与JAK相关的疾病、紊乱或症状。
• 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF
  申请人：Harada Hironori

  公开号：US20120178735A1

  公开（公告）日：2012-07-12

  Provided is a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action. The 2H-chromene compound or derivative is particularly useful for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

  提供了一种2H-色烯化合物或其衍生物，具有优异的S1P1激动剂作用。该2H-色烯化合物或衍生物特别适用于预防和/或治疗由不良淋巴细胞浸润引起的疾病或由细胞异常增殖或堆积引起的疾病。
• 2H-chromene compound and derivative thereof
  申请人：Astellas Pharma Inc.

  公开号：US08193378B2

  公开（公告）日：2012-06-05

  Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells. According to the present invention, a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient of an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells can be provided. The 2H-chromene compound and a derivative thereof which are the compounds of the present invention have an S1P1 agonist action, and can be used particularly for prevention and/or treatment of a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

  本发明提供了一种具有出色的S1P1激动剂作用的化合物，特别适用于作为预防和/或治疗由不良淋巴细胞浸润引起的疾病或由细胞异常增殖或堆积引起的疾病的活性成分。根据本发明，可以提供一种具有出色的S1P1激动剂作用的2H-香豆素化合物或其衍生物，特别适用于作为预防和/或治疗由不良淋巴细胞浸润引起的疾病或由细胞异常增殖或堆积引起的疾病的活性成分。本发明的化合物2H-香豆素及其衍生物具有S1P1激动剂作用，特别适用于预防和/或治疗由不良淋巴细胞浸润引起的疾病或由细胞异常增殖或堆积引起的疾病。
• DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK
  申请人：Dong Qing

  公开号：US20110136780A1

  公开（公告）日：2011-06-09

  Disclosed are JAK inhibitors of formula I where G 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  本发明公开了化学式I的JAK抑制剂，其中G1、R1、R2、R3、R4、R5、R6和R7在说明书中有定义。本发明还公开了含有这些化合物的制药组合物、工具箱和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗免疫系统和炎症相关的疾病、疾病和病情的方法，包括类风湿性关节炎、血液系统恶性肿瘤、上皮癌（即癌症）和与JAK相关的其他疾病、疾病或病情。
• Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08785429B2

  公开（公告）日：2014-07-22

  Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  本发明涉及公开了式I的JAK抑制剂，其中G1，R1，R2，R3，R4，R5，R6和R7在规范中定义。还公开了含有这些化合物的制药组合物、工具包和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗涉及免疫系统和炎症的疾病、障碍和状况的方法，包括类风湿性关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他与JAK相关的疾病、障碍或状况。